{"id":44296,"date":"2022-05-24T20:01:41","date_gmt":"2022-05-24T18:01:41","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/dr-reddys-laboratories-and-senores-pharmaceuticals-inc-announce-the-launch-of-ketorolac-tromethamine-tablets-usp-10-mg-in-the-u-s-market\/"},"modified":"2022-05-24T20:01:41","modified_gmt":"2022-05-24T18:01:41","slug":"dr-reddys-laboratories-and-senores-pharmaceuticals-inc-announce-the-launch-of-ketorolac-tromethamine-tablets-usp-10-mg-in-the-u-s-market","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/dr-reddys-laboratories-and-senores-pharmaceuticals-inc-announce-the-launch-of-ketorolac-tromethamine-tablets-usp-10-mg-in-the-u-s-market\/","title":{"rendered":"Dr. Reddy’s Laboratories and Senores Pharmaceuticals, Inc. announce the launch of Ketorolac Tromethamine Tablets USP, 10 mg in the U.S. market"},"content":{"rendered":"
\n

HYDERABAD, India & PRINCETON, N.J.–(BUSINESS WIRE)–#DRREDDY<\/a>–Dr. Reddy\u2019s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as \u201cDr. Reddy\u2019s\u201d) and Senores Pharmaceuticals, Inc. today announced the launch of Ketorolac Tromethamine Tablets USP, 10 mg, a therapeutic generic equivalent of the reference listed drug Toradol Tablets, 10 mg in the U.S. market approved by the U.S. Food and Drug Administration (USFDA).\n<\/p>\n

<\/a><\/p>\n

\nKetorolac Tromethamine Tablets USP, 10 mg, is a nonsteroidal anti-inflammatory drug (\u201cNSAID\u201d) indicated for the short-term (up to 5 days in adults) management of moderately severe acute pain that requires analgesia at the opioid level and only as continuation treatment following intravenous or intramuscular dosing of ketorolac tromethamine, if necessary.\n<\/p>\n

\n\u201cWe are pleased to partner with Dr. Reddy\u2019s Laboratories for the commercial launch of Ketorolac Tromethamine Tablets in the U.S. market,\u201d states Dhananjay Barot, Director, Senores Pharmaceuticals, Inc.\n<\/p>\n

\n\u201cOur constant dedication has contributed to expanding our product portfolio, and today we are a significant and reliable supplier of this product,\u201d states Swapnil Shah, Managing Director, Senores Group.\n<\/p>\n

\n\u201cWe are excited about this launch, and pleased to partner with Senores to create affordable access to this product and expand our portfolio in the U.S. market,\u201d says Marc Kikuchi, CEO, North America Generics, Dr. Reddy\u2019s Laboratories.\n<\/p>\n

\nThe Toradol Tablets, 10 mg brand and generic had U.S. sales of approximately $16.8 million MAT for the most recent twelve months ending in March 2022 according to IQVIA*.\n<\/p>\n

\nDr. Reddy\u2019s Ketorolac Tromethamine Tablets USP, 10 mg, are available in bottle count sizes of 100.\n<\/p>\n

\nPlease click here<\/a> to see the full prescribing information and approved indication, along with boxed warning for Dr. Reddy\u2019s Ketorolac Tromethamine Tablets USP, 10 mg.\n<\/p>\n\n\n
\n

\n\u00a0\n<\/p>\n

\nBOXED WARNING<\/b>\n<\/p>\n

\n\u00a0\n<\/p>\n

\nKetorolac tromethamine tablets, a nonsteroidal anti-inflammatory drug (NSAID), are indicated for the short-term (up to 5 days in adults), management of moderately severe acute pain that requires analgesia at the opioid level and only as continuation treatment following IV or IM dosing of ketorolac tromethamine, if necessary. The total combined duration of use of ketorolac tromethamine tablets and ketorolac <\/b>tromethamine should not exceed 5 days.<\/b>\n<\/p>\n

\n\u00a0\n<\/p>\n

\nKetorolac tromethamine tablets are not indicated for use in pediatric patients and they are NOT indicated for minor or chronic painful conditions. Increasing the dose of ketorolac tromethamine tablets beyond a daily maximum of 40 mg in adults will not provide better efficacy but will increase the risk of developing serious adverse events.<\/b>\n<\/p>\n

\n\u00a0\n<\/p>\n

\nGASTROINTESTINAL RISK<\/b>\n<\/p>\n

\n\u00a0\n<\/p>\n